Specify a stock or a cryptocurrency in the search bar to get a summary
Larimar Therapeutics Inc
ZA71Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania. Address: Three Bala Plaza East, Bala Cynwyd, PA, United States, 19004
Analytics
WallStreet Target Price
25 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ZA71
Dividend Analytics ZA71
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ZA71
Stock Valuation ZA71
Financials ZA71
Results | 2019 | Dynamics |